Publicaciones (205) Publicaciones de José Ignacio Fernández de Trocóniz Fernández

2024

  1. Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab

    Clinical Pharmacology and Therapeutics, Vol. 116, Núm. 5, pp. 1304-1313

  2. Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice

    Acta Pharmacologica Sinica

  3. How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children

    Antimicrobial Agents and Chemotherapy, Vol. 68, Núm. 6

  4. Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

    Blood Advances

  5. Mechanism-Based Modeling of Perioperative Variations in Hemoglobin Concentration in Patients Undergoing Laparoscopic Surgery

    Anesthesia and Analgesia, Vol. 138, Núm. 1, pp. 141-151

  6. Model-Based Assessment of the Liver Safety Profile of Acetaminophen to Support its Combination Use with Topical Diclofenac in Mild-to-Moderate Osteoarthritis Pain

    Pain and Therapy, Vol. 13, Núm. 1, pp. 127-143

  7. Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations

    European Journal of Drug Metabolism and Pharmacokinetics, Vol. 49, Núm. 4, pp. 507-516

  8. Model-Based Meta-Analysis Supporting the Combination of Acetaminophen and Topical Diclofenac in Acute Pain: A Therapy for Mild-to-Moderate Osteoarthritis Pain?

    Pain and Therapy, Vol. 13, Núm. 1, pp. 145-159

  9. Pharmacokinetic/pharmacodynamic modeling of cortical dopamine concentrations after quetiapine lipid core nanocapsules administration to schizophrenia phenotyped rats

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 13, Núm. 4, pp. 638-648

  10. The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model

    Pediatric Drugs, Vol. 26, Núm. 3, pp. 331-346

2023

  1. A physiologically based pharmacokinetic model for V937 oncolytic virus in mice

    Frontiers in Pharmacology, Vol. 14

  2. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling

    Clinical Pharmacology and Therapeutics, Vol. 114, Núm. 3, pp. 623-632

  3. Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

    PLoS Computational Biology, Vol. 19, Núm. 10

  4. Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases

    Pharmaceutics, Vol. 15, Núm. 11

  5. Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 3, pp. 1115-1126

  6. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation

    European Journal of Pharmaceutical Sciences, Vol. 183

2022

  1. A method to assess model-based bioequivalence

    Revista Colombiana de Ciencias Químico-Farmacéuticas, Vol. 51, Núm. 3, pp. 1578-1579

  2. Comparison of two pharmacokinetic–pharmacodynamic models of rocuronium bromide during profound neuromuscular block: analysis of estimated and measured post-tetanic count effect

    British Journal of Anaesthesia, Vol. 128, Núm. 3, pp. 473-481

  3. IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET)

    Trials, Vol. 23, Núm. 1

  4. IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity

    Trials, Vol. 23, Núm. 1